SCHEMBL7350806

SCHEMBL7350806

COc1ccc(S(=O)(=O)N(CCCCc2ccccc2)CC(=O)NO)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 5/20 1.00
BMP1 P13497 6/20 0.77
MEP1B Q16820 3/20 0.71
MMP1 P03956 3/20 0.69
MMP13 P45452 2/20 0.69
MMP8 P22894 2/20 0.69
MMP7 P09237 1/20 0.69
MMP12 P39900 1/20 0.69
ALDH1A1 P00352 1/20 0.67
TP53 P04637 3/20 0.64
MMP2 P08253 3/20 0.63
MMP9 P14780 2/20 0.63
ADAM10 O14672 1/20 0.63
ADAM17 P78536 1/20 0.63
MEP1A Q16819 1/20 0.63
MAPT P10636 1/20 0.63
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
MMP14 P50281 1/20 0.60
MMP16 P51512 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7352054 0.97 MMP3 (0.94) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL6415304 0.93 BMP1 (0.89) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL7109267 0.87 BMP1 (1.00) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL7338644 0.86 MEP1B (0.81) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL8177194 0.84 MMP1 (0.76) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL6418955 0.84 MMP1 (0.76) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL8175150 0.84 MMP1 (0.76) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL7004497 0.83 BMP1 (0.89) BMP1
SCHEMBL19872760 0.83 MMP1 (0.74) MMP3BMP1MEP1BMMP1MMP13
SCHEMBL14647109 0.83 MMP3 (0.71) MMP3BMP1MMP1MMP13ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0766672-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS NOVARTIS AG (CH) 2000-10-04 EP disclosed
EP-0606046-B1 Arylsulfonamido-substituted hydroxamic acids CIBA GEIGY AG (CH) 1997-10-08 EP disclosed
US-5646167-A ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
EP-0766672-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS Novartis AG (CH) 1997-04-09 EP disclosed
WO-1996040101-A1 CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS NOVARTIS AG (CH) 1996-12-19 WO disclosed
US-5552419-A METALLOPROTEINASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-09-03 US disclosed
US-5506242-A METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
WO-1996000214-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS CIBA-GEIGY AG (CH) 1996-01-04 WO disclosed
US-5455258-A Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0606046-A1 Arylsulfonamido-substituted hydroxamic acids CIBA-GEIGY AG (CH) 1994-07-13 EP disclosed